BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 37795365)

  • 21. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PROTAC therapy as a new targeted therapy for lung cancer.
    Li JW; Zheng G; Kaye FJ; Wu L
    Mol Ther; 2023 Mar; 31(3):647-656. PubMed ID: 36415148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
    Landré V; Rotblat B; Melino S; Bernassola F; Melino G
    Oncotarget; 2014 Sep; 5(18):7988-8013. PubMed ID: 25237759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Redirecting the specificity of tripartite motif containing-21 scaffolds using a novel discovery and design approach.
    VanDyke D; Xu L; Sargunas PR; Gilbreth RN; Baca M; Gao C; Hunt J; Spangler JB
    J Biol Chem; 2023 Dec; 299(12):105381. PubMed ID: 37866632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system.
    Poirson J; Biquand E; Straub ML; Cassonnet P; Nominé Y; Jones L; van der Werf S; Travé G; Zanier K; Jacob Y; Demeret C; Masson M
    FEBS J; 2017 Oct; 284(19):3171-3201. PubMed ID: 28786561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the ubiquitin pathway for cancer treatment.
    Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W
    Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Multifaceted Role of the Ubiquitin Proteasome System in Pathogenesis and Diseases.
    Stekel Z; Sheng Y; Zhang W
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PROTAC-induced proteolytic targeting.
    Carmony KC; Kim KB
    Methods Mol Biol; 2012; 832():627-38. PubMed ID: 22350917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted protein degradation by PROTACs.
    Neklesa TK; Winkler JD; Crews CM
    Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
    Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
    J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Ubiquitin System: An Emerging Therapeutic Target for Lung Cancer.
    Jin JO; Puranik N; Bui QT; Yadav D; Lee PC
    Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From Discovery to Bedside: Targeting the Ubiquitin System.
    Wertz IE; Wang X
    Cell Chem Biol; 2019 Feb; 26(2):156-177. PubMed ID: 30554913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ubiquitination and the ubiquitin - proteasome system in the pathogenesis and treatment of squamous head and neck carcinoma.
    Voutsadakis IA
    Anticancer Res; 2013 Sep; 33(9):3527-41. PubMed ID: 24023278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology.
    Cecchini C; Tardy S; Ceserani V; Theurillat JP; Scapozza L
    Chimia (Aarau); 2020 Apr; 74(4):274-277. PubMed ID: 32331546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive profiling of protein ubiquitination for drug discovery.
    Xu G; Jaffrey SR
    Curr Pharm Des; 2013; 19(18):3315-28. PubMed ID: 23151132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamics in the p53-Mdm2 ubiquitination pathway.
    Brooks CL; Gu W
    Cell Cycle; 2004 Jul; 3(7):895-9. PubMed ID: 15254415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.